What Wegovy is
Wegovy® is semaglutide, a GLP-1 receptor agonist, made by Novo Nordisk and approved by the FDA. It comes two ways. The pen is a weekly injection under the skin. The tablet is taken once each morning, and it is approved for weight reduction and heart-risk reduction in adults [1]. Both are used with a reduced-calorie diet and more physical activity.
Its approvals go beyond weight. The label covers lowering the risk of major cardiovascular events in adults with established heart disease and obesity or overweight, long-term weight reduction in adults and in adolescents 12 and older with obesity, and, for the injection, a form of fatty liver disease called MASH with moderate to advanced scarring [1]. The FDA called it the first weight medicine also approved to help prevent heart attacks and strokes in that group [2].
How Wegovy works
Semaglutide is built to closely resemble GLP-1, the fullness hormone your gut releases after a meal; the label puts the match at 94% of its sequence. It acts on GLP-1 receptors in the brain areas that regulate appetite, lowers calorie intake and slows stomach emptying, and the weight it lowers is more fat than lean mass [1]. Your physician pairs it with eating and activity changes, because medicines like it are adjuncts to lifestyle change, not replacements for it [3].
Pen or pill: the practical differences
- The pen is a weekly injection under the skin of the stomach, thigh or upper arm, from a prefilled pen. A pen belongs to one person and is never shared, even with a new needle [1].
- The tablet is swallowed whole each morning on an empty stomach with a small sip of water, up to 4 ounces, followed by at least 30 minutes before eating, drinking or taking other pills [1].
- Switching between the two is possible; the label sets out how a physician moves someone from one form to the other [1].
- Price: the VevaMD membership is the same for the pen and the tablet, while the Novo Nordisk self-pay price differs by form and strength [4].
How you get Wegovy through VevaMD
Wegovy through VevaMD is two charges, and we say so up front. The first is the VevaMD membership, $149/mo or less if you prepay a quarter: it covers your board-certified physician, the prescription and your ongoing care. The second is the medication itself, which you pay to Novo Nordisk at its published self-pay price through NovoCare® Pharmacy [4]. VevaMD does not charge you for the medication, and the full numbers are in the price section above.
- Answer the private intake. A physician licensed in your state reviews it and may message you or ask for labs.
- If Wegovy® fits you, your physician chooses the pen or the tablet and sends the prescription to NovoCare® Pharmacy.
- You create your NovoCare® account and pay Novo Nordisk there; it ships the medication to you.
- Your physician stays with you through each step-up and the check-ins that follow, under the same membership.
Who Wegovy is for
Approved for
- Adults with obesity (BMI 30 or more), or with overweight (BMI 27 or more) and at least one weight-related condition [1]
- Adults with established heart disease, such as a past heart attack or stroke, and obesity or overweight, to lower the risk of further events [1]
- People who prefer a pill to an injection: the tablet is approved for adults on the same terms [1]
Not for
- Anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2 [1]
- Anyone with a serious allergy to semaglutide or to anything in the pen or tablet [1]
- Anyone pregnant or planning a pregnancy in the next 2 months, and anyone breastfeeding while on the tablet [1]
- Anyone using another semaglutide product or another GLP-1 medicine [1]
What the trials found
Weight, injection. In the trial known as STEP 1, 1,961 adults with obesity or overweight but without diabetes took Wegovy or a placebo for 68 weeks, alongside lifestyle support. Average weight change was -14.9% on semaglutide and -2.4% on placebo; 86.4% on semaglutide lost at least 5% of their weight, against 31.5% on placebo, and 50.5% lost at least 15% [5]. Across the label’s weight trials, 71% of participants were women and the average age was 48 [1].
Weight, tablet. In the OASIS 4 study, 307 adults took the Wegovy tablet or a placebo every day for 64 weeks. Average weight change was -13.6% on the tablet and -2.2% on placebo. Stomach side effects were more common on the tablet: 74.0% against 42.2% [6].
Heart. The SELECT study enrolled 17,604 adults aged 45 and older with heart disease and a BMI of 27 or more, without diabetes, and followed them for about 40 months. A heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide and 8.0% on placebo, a 20% lower risk [7]. More people stopped the drug because of side effects on semaglutide (16.6%) than on placebo (8.2%) [7].
What to expect over time
- Months 1 to 4The pen and the tablet both start low and step up, about monthly, to the maintenance amount; your physician can hold a step if side effects need time to settle [1].
- Month 4 onwardThe maintenance phase, with regular check-ins. In STEP 1 the most common side effects, nausea and diarrhea, were typically mild to moderate and eased with time [5].
- If you stopIn the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and the improvements in blood pressure and cholesterol largely faded [8]. Wegovy is meant as long-term treatment.
Side effects and the boxed warning
| Side effect | Wegovy® pen | Placebo |
|---|---|---|
| Nausea | 44% [1] | 16% |
| Diarrhea | 30% [1] | 16% |
| Vomiting | 24% [1] | 6% |
| Constipation | 24% [1] | 11% |
| Stomach pain | 20% [1] | 10% |
| Headache | 14% [1] | 10% |
Stomach side effects were mostly mild to moderate and eased with time; 4.5% of people in STEP 1 stopped semaglutide because of them [5]. Less common but serious risks on the label include pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach side effects, allergic reactions, a faster heart rate, low blood sugar with insulin or a sulfonylurea, diabetic eye complications, and aspiration under anesthesia [1]. The suicidal thoughts warning was removed from the label in February 2026 [1].
Getting the most from it. Wegovy® works alongside habits, not instead of them. NIDDK points to federal guidance of at least 150 minutes a week of moderate activity [9], and the Menopause Society advises strength training on two days of the week, with enough protein, to protect muscle in midlife [10]. Your physician can build both into your plan.
Wegovy compared with the other options
The same intake can lead to any of four options, and your physician recommends the one that fits. Compounded semaglutide is a compounded product prepared by a pharmacy: it is not FDA-approved and it is not Wegovy®. Zepbound® is the other FDA-approved brand through a membership.
| FDA status | How it is taken | How you pay at VevaMD | Main trade-offs | |
|---|---|---|---|---|
| Compounded semaglutide | Compounded, not FDA-approved | Weekly injection from a vial, with vitamin B12 | One monthly price, as low as $199/mo: physician, medication and shipping. No membership fee | The lowest monthly price, the same at every dose; you draw each dose with a syringe |
| Compounded tirzepatide | Compounded, not FDA-approved | Weekly injection from a vial, with vitamin B12 | One monthly price, as low as $299/mo: physician, medication and shipping. No membership fee | Acts on two gut-hormone receptors, GLP-1 and GIP; the same price at every dose; you draw each dose with a syringe |
| Wegovy® | FDA-approved brand | Weekly prefilled pen, or a daily tablet | A $149/mo VevaMD membership, plus the self-pay price paid to Novo Nordisk ($348–$498/mo in total for the pen) | Approved for weight and to lower heart risk in adults with heart disease; pen or pill; two separate charges |
| Zepbound® | FDA-approved brand | Weekly prefilled pen | A $149/mo VevaMD membership, plus the self-pay price paid to Eli Lilly ($448–$598/mo in total) | Approved for weight and for moderate to severe sleep apnea with obesity; prefilled pen; two separate charges |
Weight gain in perimenopause and menopause
Women aged 50 to 64 are the most represented age group among US GLP-1 users, and midlife weight gain is a common reason: aging drives most of it, and menopause adds fat gain and redistribution [11]. In a study presented at the Menopause Society’s 2026 meeting, among nearly 2,400 midlife women taking semaglutide, those who also used hormone therapy lost more weight, and kept it off better, than those who did not. It was an observational study, so it cannot prove hormone therapy caused the difference [11].